Research Analysts Offer Predictions for AXSM Q2 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research upped their Q2 2027 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report issued on Monday, October 27th. Zacks Research analyst Team now expects that the company will earn $0.97 per share for the quarter, up from their previous forecast of $0.90. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million for the quarter, compared to analysts’ expectations of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.

Several other equities analysts have also recently weighed in on the company. Royal Bank Of Canada increased their price target on Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a report on Tuesday, August 5th. Bank of America increased their price target on Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Morgan Stanley raised their target price on Axsome Therapeutics from $191.00 to $194.00 and gave the stock an “overweight” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company raised Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $178.20.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $133.33 on Wednesday. The business’s fifty day moving average price is $122.43 and its 200-day moving average price is $112.11. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of -26.30 and a beta of 0.52. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. Axsome Therapeutics has a 1-year low of $75.56 and a 1-year high of $139.13.

Institutional Investors Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Axsome Therapeutics in the first quarter worth about $25,000. Versant Capital Management Inc increased its holdings in shares of Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Axsome Therapeutics in the first quarter worth about $31,000. First Horizon Corp bought a new stake in shares of Axsome Therapeutics in the third quarter worth about $34,000. Finally, AlphaQuest LLC bought a new stake in shares of Axsome Therapeutics in the first quarter worth about $38,000. 81.49% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Mark Coleman bought 1,575 shares of Axsome Therapeutics stock in a transaction dated Monday, September 8th. The shares were purchased at an average cost of $127.28 per share, with a total value of $200,466.00. Following the completion of the acquisition, the director owned 48,212 shares of the company’s stock, valued at $6,136,423.36. This trade represents a 3.38% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $115.96, for a total value of $1,159,600.00. The SEC filing for this sale provides additional information. Insiders sold 243,332 shares of company stock valued at $28,824,746 in the last ninety days. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.